InvestmentApr 13, 2026, 04:03 PM
Allogene Therapeutics to Offer $175M in Common Stock
AI Summary
Allogene Therapeutics, Inc. announced its intention to offer and sell $175 million of its common stock in an underwritten public offering. The company also plans to grant the underwriters a 30-day option to purchase up to an additional $26.25 million in shares. Allogene expects to use the net proceeds from this offering for general corporate purposes, including clinical trial expenses, research and development, and capital expenditures.
Key Highlights
- Allogene Therapeutics intends to offer $175 million of common stock.
- Underwriters have a 30-day option for an additional $26.25 million.
- Proceeds will fund clinical trials, R&D, and general corporate purposes.
- Goldman Sachs, Jefferies, and TD Cowen are joint book-running managers.